Sign In
Buy NEO
$10.14
+0.0200 (+0.198%)
At Close: Jun 03, 2026
NeoGenomics (NEO) Surges 6.4%: Is This an Indication of Further Gains?
12:33pm, Monday, 27'th Jun 2022 Zacks Investment Research
NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
NeoGenomics (NEO) Surges 6.4%: Is This an Indication of Further Gains?
09:59am, Monday, 27'th Jun 2022
NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Analyst Ratings for NeoGenomics
04:12pm, Friday, 03'rd Jun 2022 Benzinga
Over the past 3 months, 10 analysts have published their opinion on NeoGenomics (NASDAQ:NEO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a com
NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences
04:05pm, Friday, 03'rd Jun 2022
FT. MYERS, FL / ACCESSWIRE / June 3, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announce
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022
02:08pm, Friday, 03'rd Jun 2022 Benzinga
Upgrades
Keefe, Bruyette & Woods upgraded the previous rating for Regions Financial Corp (NYSE:RF) from Underperform to Market Perform. For the first quarter, Regions Financial had an EPS of $0.55, c
Inivata and Collaborators to P resent New D ata F urther V alidat ing the A pplication of its RaDa R® MRD and InVisionFirst®-Lung Tests at the 2022 ASCO Annual Meeting
Analyst Ratings for NeoGenomics
01:13pm, Thursday, 28'th Apr 2022 Benzinga
Analysts have provided the following ratings for NeoGenomics (NASDAQ:NEO) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
5
4
0
0
Last
NeoGenomics Inc.'s (NEO) Q1 2022 Results - Earnings Call Transcript
02:58pm, Wednesday, 27'th Apr 2022
NeoGenomics, Inc. (NASDAQ:NEO ) Q1 2022 Earnings Conference Call April 27, 2022 8:30 AM ET Company Participants Lynn Tetrault - Executive Chair & Principal Executive Officer William Bonello - Chief Fi
NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
12:45pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 13.04% and 0.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: NeoGenomics (NEO) Q1 Earnings Expected to Decline
07:01pm, Wednesday, 20'th Apr 2022 Zacks Investment Research
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reata Pharmaceuticals, Inc. (RETA) Stock Jumps 14.5%: Will It Continue to Soar?
11:21am, Wednesday, 30'th Mar 2022 Zacks Investment Research
Reata Pharmaceuticals, Inc. (RETA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further s
U.S. stocks close sharply higher, S&P 500 exits correction territory on optimism about Ukraine talks
08:45pm, Tuesday, 29'th Mar 2022 MarketWatch
U.S. stock benchmarks close sharply higher Tuesday, with the S&P 500 exiting correction territory, buoyed by optimism over negotiations on a cease-fire in Ukraine and a decline in some commodity pric
NeoGenomics Stock Gets Downgrade After CEO Resigns And Other Negative Updates
03:30pm, Tuesday, 29'th Mar 2022 Benzinga
NeoGenomics, Inc. (NASDAQ: NEO) shares are getting hammered Tuesday after the cancer diagnostics company announced the abrupt resignation of CEO Mark Mallon and warned of the first-quarter shortfal
Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2022
02:04pm, Tuesday, 29'th Mar 2022 Benzinga
Upgrades
According to OTR Global, the prior rating for Illumina Inc (NASDAQ:ILMN) was changed from Mixed to Positive. For the fourth quarter, Illumina had an EPS of $0.75, compared to year-ago quarter
10 Biggest Price Target Changes For Tuesday
01:18pm, Tuesday, 29'th Mar 2022 Benzinga
BTIG cut the price target on NeoGenomics, Inc. (NASDAQ: NEO) from $35 to $28. NeoGenomics shares fell 29.2% to $12.60 in pre-market trading.
Craig-Hallum lowered Stryve Foods, Inc. (NASDAQ: SNAX)
